The global Leukocyte Reduction Filter market was valued at USD 4.28 million in 2019 and is projected to reach USD 6.02 million by 2027, expanding at a CAGR of 6.1% during the forecast period. In terms of volume, the market is projected to expand at a CAGR of 5.6% during the forecast period. The human body is responsible for leukocytes, also known as white blood cells, which fights against bacteria, viruses, and irregular cells to prevent diseases or illnesses. However, leukocytes are not well tolerated and associated with certain kinds of transfusion reactions when they are transfused into another human. Leucocytes are separated from the blood before storage to avoid transfusion reactions or diseases. Leukocyte reduction filters are used to lessen complications related to transfused white blood cells that are contained in whole blood, platelets, red blood cells, and plasma.
Rising demand for plasma and platelets for several serious therapies is expected to contribute to the market growth. Moreover, factors such as increasing occurrence of leukemia, growing number of blood donations, and growing awareness related to blood donation are anticipated to contribute to the growth of global leukocyte reduction filter market during the forecast period.
The incidence of leukemia varies between pathological types and population. A total of 437.0 thousand new cases were reported and 309.0 thousand cancer deaths were caused due to leukemia worldwide in 2018. According to the American Cancer Society, about 1.32 million individuals were diagnosed with leukemia and lymphoma are reportedly each year. Additionally, according to the National Kidney Foundation, about 10% of the global population is affected by chronic kidney disease. As a result, high prevalence and elevated incidence rates of chronic diseases have increased the demand for blood and blood supplies, which in turn, is projected to increase the demand for leukocyte reduction filter during the forecast period.
The necessity for blood products and blood is growing every year in several nations. In low and middle-income countries, demand exceeds supply, making it is difficult for blood services to make adequate blood accessible, while ensuring its quality and safety. An upsurge of 7.8 million blood donations from volunteer unpaid donors has been reported between 2013 and 2018. Around, 79 countries collect more than 90% of blood supply from voluntary unpaid blood donors; however, 56 countries collect more than 50% of their blood supply from family/replacement donors or paid donors. Based on samples from 1,000 people, the blood donation rate is 31.5 in high-income countries, 15.9 in upper middle-income countries, 6.8 in lower middle-income countries, and 5.0 donations in low-income countries. Over the last decade, the proportion of blood donations from volunteer unpaid donors has increased and 73 countries in the world are now collecting more than 90% of blood supplies from such donors. Hence, increase in blood donations is expected to increase the demand for leukocyte reduction filters during the forecast period.
The high demand for apheresis technique for blood transfusion is expected to hinder the market growth during the forecast period. The apheresis technique is used to enable operators to choose and collect specific components. Donors can donate the blood manually or to donate certain components by apheresis. Apheresis collects blood components, which offers a number of advantages as compared to the entire blood collected manually. Apheresis divides the components; therefore, no further treatment is required for the blood. Thus, the benefits associated with the apheresis technique is anticipated to impede the market growth during the forecast period.
By type, the leukocyte reduction filter market has been segmented into whole blood, red blood cell (RBC), platelet, and plasma. The whole blood segment is anticipated to account for a substantial share of the market during the forecast period; however, the platelets segment is anticipated to expand at significant pace during the forecast period. Major surgeries can lead to the loss of blood; thus requiring the use of whole blood donation. Increasing demand for blood and plasma from the geriatric population across the globe coupled with rising blood and plasma donations worldwide is expected to drive the growth of whole blood segment during the forecast period. Moreover, advancements in blood transfusion and blood testing devices drive the growth of leukocyte reduction filter market.
By end-use category, the leukocyte reduction filter market has been segmented into bed side use, laboratory use, and in-line system. The laboratory use segment is expected to hold a significant market share in 2020 due to a large number of disease screening and blood typing services prior to transfusion therapy. The safety of blood supply through thorough disease screening, while meeting regulatory standards is maintained by these facilities. In these settings, some regular tests performed on the donated blood include Rh-typing, unexpected RBC antibody checking, blood typing, and infectious disease screening.
In terms of regions, the global leukocyte reduction filters market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a significant share of the global market in 2019. The market in Asia Pacific is projected to expand at significant CAGR during the forecast period. The rise in the adoption of leukocyte reduction filters in North America is attributed to the increase in the adoption of new technology and growth in disposable revenue. The growth in geriatric population and prevalence of leukemia in this region are driving the demand for leukocyte reduction filters. In 2019, approximately 61,780 individuals were diagnosed with leukemia, according to the Leukemia and Lymphoma Society (LLS). In the US from 2011 to 2015, leukemia was the sixth common cancer claiming the lives of men and women, according to the LLS and the American Cancer Society. Moreover, increasing clinical research activities and high presence of biotech and pharmaceutical companies are fueling the market in the region.
Some frequently asked quetions about this report!
Additional company profiles can be provided on request.
Yes, the report covers product specific information such as whole blood, red blood cells (RBCs), platelets, and plasma.
According to the Growth Market Reports report, in terms of value the market leukocyte reduction filter is likely to register a CAGR of 6.1% during forecast period 2020-2027, with an anticipated valuation of USD 6.02 million by the end of the 2027.
The global leukocyte reduction filter market report provides the additional data such as patent landscape, intellectual property trends, intellectual property strategy outlook, new market players analysis, and market entry opportunities. Moreover, the report also provides the company market share analysis, cross splits on regional level and volume data for the global leukocyte reduction filter market.
The market is driven by factors such as increasing occurrence of leukemia, growing number of blood donations, increasing awareness related to blood donation, and rising demand for plasma and platelets for several serious therapies.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness a decline of 7.0% in 2020 as compared to 2019 owing to the negative impact of COVID-19.
The base year considered for the global leukocyte reduction filter market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Laboratories, hospitals, and blood centers are the key end users driving the market growth.
Major Manufactures include Haemonetics Corporation, TERUMO BCT, INC., Asahi Kasei Medical Co., Ltd., Macopharma, and Fresenius Kabi AG among others.
Some other reports from this category!